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Abstract
This study investigated the effect of sodium lauryl sulfate (SLS) on skin structural perturbation
when utilized simultaneously with low-frequency sonophoresis (LFS). Pig full-thickness skin
(FTS) and pig split-thickness skin (STS) treated with LFS/SLS and LFS were analyzed in the
context of the aqueous porous pathway model to quantify skin perturbation through changes in
skin pore radius and porosity-to-tortuosity ratio (ε/τ). In addition, skin treatment times required to
attain specific levels of skin electrical resistivity were analyzed to draw conclusions about the
effect of SLS on reproducibility and predictability of skin perturbation. We found that LFS/SLS-
treated FTS, LFS/SLS-treated STS, and LFS-treated FTS exhibited similar skin perturbation.
However, LFS-treated STS exhibited significantly higher skin perturbation, suggesting greater
structural changes to the less robust STS induced by the purely physical enhancement mechanism
of LFS. Evaluation of ε/τ values revealed that LFS/SLS-treated FTS and STS have similar
transport pathways, while LFS-treated FTS and STS have lower ε/τ values. In addition, LFS/SLS
treatment times were much shorter than LFS treatment times for both FTS and STS. Moreover, the
simultaneous use of SLS and LFS not only results in synergistic enhancement, as reflected in the
shorter skin treatment times, but also in more predictable and reproducible skin perturbation.
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INTRODUCTION
Enhancement of skin permeability by the application of ultrasound is referred to as
sonophoresis. Although the use of ultrasound for transdermal delivery of therapeutics dates
back to the 1950s, extensive research in this area has only taken place in the past two
decades.1,2 In the early years of sonophoresis research, therapeutic frequencies, ranging
from 1–3 MHz, were most common.3–5 However, a significant shift in the methodology
and understanding of sonophoresis took place once the switch was made to low-frequency
sonophoresis (LFS, utilizing frequencies in the range of 20 – 100 kHz), because it was
possible to achieve even greater skin permeability enhancements compared to therapeutic
frequencies.6 Following this shift, research on the mechanisms of LFS showed conclusively
that cavitation above the skin, in the aqueous coupling medium, is the primary mechanism
of enhancement.7,8 Much of this initial mechanistic research involving LFS was done
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utilizing pure aqueous media, containing no chemical enhancers in the coupling solution.6–9
However, another breakthrough in the field occurred when it was shown that combining
LFS with a chemical enhancer, specifically a surfactant such as sodium lauryl sulfate (SLS),
caused a synergistic effect, resulting in orders-of-magnitude improvements in skin
permeability enhancement over the application of LFS alone.10–14 Since that time, the
synergistic effect between chemical enhancers (mainly SLS) and LFS has been well
documented,2,10–12,15 although the precise physical mechanisms responsible for the
observed synergism are still not well understood. Nearly all previous studies on LFS/SLS
synergism have focused primarily on the effect of a simultaneous SLS and LFS treatment in
order to increase skin permeability to different solutes. Although the extent to which LFS/
SLS enhances skin permeability, relative to LFS alone, is generally well understood, very
little is known about how these synergistic enhancers affect the skin structure itself. To date,
only a small number of publications have commented on the structural changes in skin
treated with LFS/SLS and LFS.16–18 These studies provided useful microscopy-based
insight into the structural changes that occur when LFS/SLS and LFS are applied to skin. In
the present study, the aqueous porous pathway model is implemented to probe changes in
skin structural parameters and to draw quantitative conclusions about the role of SLS in
inducing skin perturbation.
With the above in mind, it is clear that a quantitative study investigating the effect of LFS/
SLS on skin structural parameters, compared to that of LFS alone, would provide significant
insight on how adding SLS to the LFS coupling medium affects skin perturbation.
Furthermore, because LFS/SLS combines both physical and chemical enhancement
mechanisms, while LFS acts solely in a physical manner, it is likely that the mechanical
properties of the skin model used may also play an important role in determining the extent
of skin perturbation.9,19,20 Specifically, pig full-thickness skin (FTS), which possesses a
full dermal backing, may impart increased mechanical support to the skin in response to the
physical perturbation induced by LFS, relative to pig split-thickness skin (STS, dermatomed
to 700 µm thickness). In fact, Seto et al. have recently shown that when treating skin with
LFS/SLS at 20 kHz, the thickness of the skin plays a significant role in determining the
extent of skin perturbation in human skin models (250 µm STS, 700 µm STS, and FTS),
while in pig skin models, skin thickness does not play a significant role (700 µm STS and
FTS).19 Moreover, the difference in LFS/SLS treatment times for pig and human 700 µm
STS reported by Seto et al. led the authors to propose that intrinsic skin differences (e.g.,
dermal elastic fiber content) may explain the observed differences. In this manuscript, we
utilize an approach similar to the one used by Seto et al. to gauge overall skin perturbation.
Specifically, we utilize the aqueous porous pathway model to calculate two skin structural
parameters: (i) log C, which is related to the average radius of the aqueous skin pores, and
(ii) the porosity-to-tortuosity ratio (ε/τ). We compare the structural parameters of skin
treated with LFS/SLS and LFS to that of untreated skin (for both FTS and STS), to better
understand the effect of SLS on skin structural perturbation and transdermal pathways when
utilized in combination with LFS. Furthermore, we also explore the reproducibility and
predictability of the LFS/SLS and LFS treatments by comparing: (i) the width of the 95%
confidence intervals for the structural parameters calculated, (ii) the correlation coefficient
observed between the permeability and the resistivity of skin samples (see Theory section),
and (iii) the trends observed in treatment times for skin samples treated to different extents
of skin electrical resistivity. Clearly, the reproducibility and predictability of skin
permeability enhancement are essential for the successful clinical implementation of this
technology.21,22
With the above motivation and background in mind, it is important to stress that the study
presented here is the first one to investigate the synergism between LFS and SLS in the
context of quantifying skin structural perturbation, while utilizing a fixed skin electrical
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resistivity protocol. It is noteworthy that previous studies have focused primarily on fixed
treatment time protocols (typically treating skin samples with LFS for 10 minutes in the
presence and in the absence of SLS).11,12,15 The present study differs from previous ones
in that we treated skin samples with both LFS/SLS and LFS to attain a wide range of skin
electrical resistivity levels, allowing treatment times to vary in order to reach those levels.
This modification in the treatment protocol is significant, because treating skin samples with
LFS for a fixed period of time does not ensure that the skin samples are perturbed to any
significant extent. Indeed, skin permeability enhancement is usually modest under this type
of treatment protocol, since LFS application for 10 minutes results in just a 1.5-fold
enhancement in skin electrical resistivity.12 Note that this is a very small extent of skin
electrical resistivity enhancement, considering that skin hydration itself can cause similar
extents of enhancement during a 24-hour period.12 Accordingly, in the present study, we
require that LFS be applied to attain greater enhancements in skin electrical resistivity,
which allows us to better understand the effect of the purely physical enhancement
mechanism associated with LFS, relative to the combined physical and chemical
enhancement mechanisms associated with LFS/SLS.
Along the lines discussed above, the objectives of the present study are to explain: i) how
the extent of skin perturbation differs between skin samples treated with LFS/SLS and LFS,
in the context of the aqueous porous pathway model, ii) how ε/τ ratios differ between skin
samples treated with LFS/SLS and LFS, iii) how the amount of mechanical support (i.e., the
thickness of the dermis in the skin model considered) affects the extent of skin perturbation
in samples treated with LFS/SLS and LFS, and iv) how the reproducibility and predictability
of skin permeability enhancement and treatment times of skin samples treated with LFS/SLS
compares to those of skin samples treated solely with LFS. Addressing (i) – (iv) will help
explain the role of SLS in inducing skin structural perturbation, including the role of SLS in
enhancing transdermal transport.
MATERIALS AND METHODS
Chemicals
Phosphate buffered saline tablets (PBS; 0.01 M phosphate, 0.137 M NaCl) and SLS were
obtained from Sigma Chemical Company (St. Louis, MO). C14-labeled sucrose (specific
activity of 600 mCi/mmol) was obtained from American Radiolabeled Chemicals (St. Louis,
MO). Hionic-Fluor, a scintillation cocktail, was obtained from Perkin-Elmer (Waltham,
MA). All chemicals were used as received. Deionized water from a Milli-Q water
purification system (Millipore, Bedford, MA) was used for the preparation of all solutions.
Preparation and Pre-Treatment of Skin Samples by LFS/SLS
Previously published protocols were utilized for the storage and preparation of skin samples.
14,19 This procedure has been approved by the MIT Committee on Animal Care. Briefly,
skin was harvested from the back and flank of Female Yorkshire pigs, sectioned into 25-mm
strips, and stored at −85 °C for up to 6 months. Before use in experiments, the skin was
thawed for 1 hour in PBS and all excess hair and subcutaneous fat were removed. Full-
thickness skin (FTS) samples were utilized without further preparation, while split-thickness
skin (STS) samples were dermatomed to 700 µm thickness using an electric reciprocating
dermatome (Zimmer Orthopedic Surgical Products, Dover, OH). The skin was then cut into
25 mm by 25 mm samples, for use in the 15-mm inner diameter diffusion cells (PermeGear,
Hellertown, PA).
LFS/SLS and LFS pre-treatment of skin samples was carried out according to previously
published methods.12,13,17,19,20,24 Skin treatment was carried out with a 20 kHz
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ultrasound horn (VCX 500, Sonics and Materials, Inc., Newtown, CT), under the following
experimental conditions: intensity - 7.5 W/cm2, duty cycle - 50% (5 s on, 5 s off), and tip
displacement - 3 mm. Two different coupling media were utilized to treat the skin samples:
i) 1% SLS in PBS solution (LFS/SLS treatment), and ii) PBS solution alone (LFS
treatment). Samples were treated with LFS until they reached currents ranging from 5 µA
(low level of LFS treatment) to 200 µA (high level of LFS treatment), in order to test a wide
range of LFS-induced skin perturbation (higher currents suggest higher levels of skin
perturbation). Note that the range of skin currents used here is similar to previously reported
ranges used with LFS.19,25 After each minute of LFS treatment, the coupling medium was
changed in order to minimize thermal effects (maintain the temperature within 10 °C of
room temperature), and the electrical current of the skin samples was measured to determine
if a desirable skin current had been attained. Following LFS treatment, samples were rinsed
thoroughly with PBS in order to remove all excess SLS from the skin surface, and the
coupling medium was replaced with PBS prior to the sucrose permeability experiments.
Skin Electrical Resistivity Measurements
Skin electrical resistivity, R, has been shown to be an accurate and instantaneous indicator of
the structural state of the skin.9,19,23 Previously published methods9,24,25 were followed
to measure R and are summarized next. A signal generator (Hewlett-Packard, model HP
33120A) was used to generate an AC voltage at 100 mV and 10 Hz. The voltage was
applied across the skin using two Ag/AgCl electrodes (In Vivo Metrics, Healdsburgh, CA).
The skin electrical current was measured using a multimeter (Fluke Corporation, Model
189) and the skin electrical resistance was calculated using Ohm’s Law. R was then
calculated by subtracting the background resistance and then multiplying the resulting skin
electrical resistance by the area of the skin sample. In order to ensure that the skin was intact
prior to experimentation, the initial R value of a skin sample was required to be above 50
kOhm·cm2.26–28
Calculating the Steady-State Sucrose Skin Permeability
Following the LFS/SLS or LFS treatments, the steady-state sucrose skin permeability was
determined. Sucrose was chosen as a model hydrophilic permeant because it has previously
been utilized in the context of the aqueous porous pathway model to accurately describe skin
perturbation with LFS/SLS through the measurement of aqueous pore radii and the
calculation of ε/τ values.19,20 Before commencing the permeability experiments, skin
samples were remounted into clean, dry diffusion cells, and filled with 12 mL of PBS in the
receiver chamber. For both the LFS/SLS-treated and the LFS-treated skin samples, 2 mL of
donor solution containing 0.3–5 µCi/mL of C14-labeled sucrose was utilized. For the passive
skin samples, 0.75–1.0 mL of donor solution containing 25–50 µCi/mL of C14-labeled
sucrose was utilized (note that a higher concentration is necessary because of the low
permeability of the untreated skin samples, and therefore, a smaller donor volume is utilized
to minimize the amount of radiolabeled chemicals used). The radiolabeled sucrose
concentrations were chosen such that the level of radioactivity in the receiver chamber
aliquots was significantly greater than the background radioactivity levels (approximately
10-fold greater). The receiver chambers were stirred magnetically at 400 rpm.
The diffusion cells were sampled every two hours, between 18 and 26 hours, in order to
measure the steady-state sucrose permeability of the skin samples. Note that this time frame
has previously been established as being appropriate for measuring the steady-state
permeability of sucrose through porcine skin.19,20 For skin samples treated with LFS/SLS
or LFS, 200-µL aliquots of the donor solutions and 400-µL aliquots of the receiver solutions
were withdrawn at each time point, in addition to measuring R. For passive skin samples,
20-µL aliquots of the donor solutions and 500-µL aliquots of the receiver solutions were
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withdrawn at each time point. Upon withdrawal of solution from the receiver chamber, an
identical volume of PBS was added in order to keep the solution level constant. The
concentration of sucrose in each sample was measured by adding 5 – 15 mL of scintillation
cocktail to each sample and then analyzing the samples on a Tri-Carb 2810TR liquid
scintillation counter (PerkinElmer, Waltham, MA).
The permeability of sucrose through the skin, P, was calculated at steady-state, infinite sink
conditions using the following equation:20
(1)
where A is the area of skin available for permeation, V is the volume of PBS in the receiver
chamber, Cd is the average sucrose concentration in the donor chamber over the sampling
period, and (ΔC/Δt) is the rate of change of sucrose concentration in the receiver chamber
(where replacement of the sampled aliquots by PBS is taken into account).
THEORY
The Aqueous Porous Pathway Model
By assuming that a hydrophilic permeant, such as sucrose, follows a similar path through the
skin as the current carrying ions (for PBS, the dominant ions are Na+ and Cl−), one can
utilize the aqueous porous pathway model to calculate meaningful structural parameters of
the skin.20 This model utilizes hindered-transport theory29 in order to quantify the steric
hindrance exerted by the finite radius of the skin pores on the fluxes of the aqueous
permeant and the current carrying ions through the skin. The hindrance factors
corresponding to both species are related solely to the radius of each permeant and to the
average radius of the aqueous skin pores, rpore. Then, by equating the diffusion of the
aqueous permeant, which is related to the skin permeability, P, and the diffusion of the
current carrying ions, which is related to the skin electrical resistivity, R, one can determine
a log C value (see Eq. (2) below), which is related to rpore and the extent of skin structural
perturbation.
The relation between skin permeability, P, and skin electrical resistivity, R, in the context of
the aqueous porous pathway model, is given by:20
(2)
where C is defined as follows:
(3)
where z is the electrolyte valence, F is Faraday’s constant, cion is the electrolyte molar
concentration, e0 is the electronic charge, k is the Boltzmann constant, T is the absolute
temperature,  is the infinite-dilution diffusion coefficient of solute i, H(λi) is the
hindrance factor for solute i, and λi is defined as the ratio of the radius of solute i, ri, to the
radius of the aqueous skin pores, rpore.13 The most up-to-date expression for H(λi), which is
valid for λi ≤ 0.95, is given by:14,19,29
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(4)
It is important to note that the only variable in Eq. (3) that depends on the intrinsic
properties of the skin is rpore (which appears through λp and λion). All the other variables are
either constants or are properties of the permeants used. Therefore, once an experimental C
value is determined using Eq. (2), rpore can be determined by iteratively solving Eq. (3) until
it converges.
Before applying the aqueous porous pathway model to an experimental data set, it is first
necessary to determine whether the model is applicable. To this end, a linear regression is fit
to each set of log P versus log R data sets, and only if a 95% confidence interval on the slope
of the regression includes the theoretical value of −1 (see Eq. (2)) and the linear regression
is found to be statistically significant, is the model assumed to be valid. For a more detailed
discussion on the applicability of the aqueous porous pathway model, see Seto et. al.19
After confirming that the data set can be described by the aqueous porous pathway model, a
log C value is determined using Eq. (2) for each data point contained within the data set.
Subsequently, all the individual log C values are averaged to yield the log C value
corresponding to that data set. The average log C value can then be utilized to calculate rpore
and to assess the structural perturbation of the skin.
It is important to stress that, for any aqueous permeant utilized (with given hydrodynamic
radius), only a certain range of rpore values can be determined. In fact, for any permeant,
there will be an upper bound on the value of rpore that can be probed depending on the
hydrodynamic radius of the permeant (the hydrodynamic radius of sucrose is estimated to be
5.5 Å20). This follows, because as the pores become increasingly large, the amount of
hindrance exerted by the pores on the diffusing permeants becomes increasingly small as the
hindrance factor approaches unity. Recall that hindrance factors range from 0 to 1, where a
hindrance factor of 1 corresponds to no hindrance, and a hindrance factor of 0 corresponds
to infinite hindrance. Beyond a certain rpore value, the hindrance exerted by the pores on the
permeant becomes statistically indistinguishable from the diffusion of the permeant at
infinite dilution, which corresponds to the upper bound of rpore (calculated from the
corresponding upper bound on log C) that can be probed with that permeant. This infinite-
dilution limit (or infinite-pore limit) will be attained at lower rpore values for smaller
permeants and will be higher for larger permeants. The infinite-pore limit for sucrose has
been previously established to be ~120 Å (based on Eq. (4)).19,20 Therefore, for pore radii
which are larger than the upper bound for sucrose, log C values can still be used to compare
relative skin perturbations of different skin samples.
In addition to calculating log C and rpore values in the context of the aqueous porous
pathway model, we can also use this model to compute the porosity-to-tortuosity ratio (ε/τ)
of the skin samples. This allows us to gain deeper insight into the transdermal pathways
present within the skin, by understanding the importance of the area of skin pores present on
the skin surface (reflected in ε) relative to the length of the aqueous pathways present in the
skin (reflected in τ). Specifically, ε/τ is given by the following expression:20
(5)
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where σsol is the electrical conductivity of PBS (0.012 Ω−1`cm−1),20 H(λion) is the
hindrance factor for an ion calculated using Eq. (4), and Δx is the thickness of the skin layer
that provides the primary barrier to transport, which is assumed to be the thickness of the
stratum corneum (13.1 µm).13,30
RESULTS
Analysis of the Experimental Data in the Context of the Aqueous Porous Pathway Model
In order to verify that the aqueous porous pathway model is valid over the range of R values
attained using the LFS/SLS and LFS skin treatments, we determined if the regressed slopes
are not significantly different from the theoretical value of −1 (see Eq. (2)). The log P-log R
plots generated for this analysis are reported in Figure 1, with the resulting linear regression
parameters listed in Table I. Note that a subset of the LFS/SLS data has been published in
19. Table I shows that the 95% confidence intervals on the slopes of all 6 sample sets tested
include the theoretical value of −1, thus validating use of the model.* After establishing the
applicability of the aqueous porous pathway model, we proceed next to calculate skin
structural parameters to assess the effect of SLS on skin perturbation, when utilized
simultaneously with LFS.
Evaluation of Skin Perturbation through a Comparison of Log C Values
To assess the overall skin perturbation of the two LFS/SLS-treated and two LFS-treated skin
models, an analysis-of-variance (ANOVA) test was performed on all the log C values
corresponding to the four sample groups tested (see Table II). The ANOVA test yielded
P<0.0001 (note that, at 95% confidence, P must be below 0.05 to reject the null hypothesis
that all the sample groups tested have the same population mean), indicating that one or
more of the four sample groups do not contain the same population mean. Additional
analysis showed that there is no statistical difference in the log C values of the two LFS/
SLS-treated skin models (FTS and STS), while there is significant statistical difference
between FTS and STS treated solely with LFS (P<0.0001). Next, an ANOVA test was
performed on the LFS/SLS-treated FTS and STS models, along with the LFS-treated FTS
model, and no statistical difference in the log C values of these three skin models was
observed. Pairwise t-tests assuming unequal variances between the log C values of all the
four skin models confirmed that the LFS-treated STS model exhibits a significantly different
extent of skin perturbation compared to the other three skin models tested, while none of the
other three skin models tested are statistically different from each other.
As a reference point, log C values for untreated FTS and STS were also determined, and the
two LFS/SLS-treated and two LFS-treated skin models were found to have significantly
different log C values than the untreated skin samples (pairwise t-tests at 95% confidence).
Furthermore, a comparison of untreated FTS and untreated STS showed no statistical
difference in their log C values. Utilizing Eqs. (3) and (4), the average aqueous pore radius
of untreated FTS was found to be 16.4 Å (95% confidence interval of [13.6 Å, 21.8 Å]), and
that of STS was found to be 16.6 Å (95% confidence interval of [14.2 Å, 20.5 Å]). Note that
for the LFS/SLS-treated and LFS-treated skin samples, the calculated pore radii were above
the infinite-pore limit (see Theory section) and, therefore, only log C values were used to
compare the extent of skin structural perturbation of these skin models.
*Note that for the passive skin samples (samples with no LFS/SLS or LFS treatments), there is greater uncertainty in the slope of the
data, as reflected in the large range for the 95% confidence intervals for these two data sets (1.48 and 0.87, respectively). This is
expected, because the passive skin samples have very similar electrical resistivities due to the inherent barrier properties of the skin,
and because we require that the skin samples have a certain initial electrical resistivity to ensure their integrity. Therefore, any natural
variation in skin permeability, or in skin pore radius distribution, will result in relatively large deviations from expected values and
cause greater uncertainty in the regressed values.
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Evaluation of the Skin Structural Parameter, ε/τ
ε/τ values were calculated using Eq. (5) for the two LFS/SLS-treated and two LFS-treated
skin samples, as well as for untreated FTS and STS. These results are reported in Table II.
The ε/τ values of both LFS/SLS-treated FTS and STS are identical, while the ε/τ values of
the LFS-treated FTS and STS groups are lower, and generally decrease with decreasing skin
thickness. There is no statistical difference between the ε/τ values of untreated FTS and STS.
On average, ε/τ was found to increase approximately 20-fold between untreated skin
samples and samples that were treated with LFS/SLS or LFS, suggesting an increase in the
number of pores on the skin (reflected in a larger ε value) or the creation of more direct (less
tortuous) paths through the skin (reflected in a smaller τ value) following treatment of the
skin.
Treatment Time Required to Reach Specific Skin Electrical Resistivity Levels
In order to assess reproducibility and predictability of the LFS/SLS and LFS treatment
regimens, in addition to the regression analyses (r2 values and 95% confidence intervals)
reported in Tables I and II, treatment times were compared for each of the two treatment
conditions (with and without SLS) at three separate skin perturbation levels (as quantified by
R values of 1.5, 4.0, and 10.0 kΩ·cm2±40%). Note that a smaller skin electrical resistivity
value corresponds to a greater extent of skin perturbation (less resistance of the skin
membrane). This data is reported in Table III. For LFS/SLS-treated skin samples, treatment
times increased monotonically with decreasing skin electrical resistivity. In addition,
treatment times were not significantly different between FTS and STS samples at each of the
skin electrical resistivities considered. On the other hand, the treatment times for skin
samples treated solely with LFS did not behave in a straightforward manner, and took 5-fold
to 12-fold longer to reach skin electrical resistivity levels similar to those of skin samples
treated with LFS/SLS. In addition, no statistically significant difference was found between
the treatment times required to reach any of the three skin electrical resistivities considered
in the case of LFS-treated FTS.
DISCUSSION
Effect of SLS on the Structural Perturbation of LFS-Treated Skin
The primary criterion that we used to quantify skin perturbation utilizes the effective radii of
the hydrophilic diffusive pathways in the skin models tested, which scale directly with log C
in the context of the aqueous porous pathway model (see Eqs. (2) – (4)). A less negative log
C value indicates an increase in the pore radius, suggesting increased perturbation of the
skin samples by the treatment administered. Our main objective was to compare the results
for skin samples treated with LFS/SLS with those for skin samples treated only with LFS, in
order to understand the effect of SLS on skin perturbation when used simultaneously with
LFS. In addition, in order to test the effect of the skin mechanical support on skin
perturbation, for the two skin treatments used (LFS/SLS and LFS), both FTS (typical
thickness of 1.5–1.8 mm) and STS (thickness of 0.70 mm) models were tested. It is
important to recognize that both the FTS and STS models are equivalent, in the context of
the aqueous porous pathway model, prior to treatment, as clearly reflected in their: (i) nearly
identical log C values (see Table II, corresponding to pore radii of 16.4 Å and 16.6 Å,
respectively), and (ii) their statistically similar values of ε/τ (see Table II). Therefore, any
observed increases in log C or ε/τ in the treated skin samples can be attributed solely to the
LFS/SLS or LFS treatments applied to those skin samples.
Comparison of the LFS/SLS-Treated FTS and STS Models—A comparison of the
skin structural parameters of LFS/SLS-treated FTS and STS shows that: (i) their log C
values are statistically similar (see Table II), and (ii) their ε/τ values are essentially identical
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(see Table II). Furthermore, Table III shows that the treatment times associated with the
three levels of skin electrical resistivity for FTS and STS are statistically similar for the three
skin electrical resistivities analyzed. This confirms that, irrespective of the skin thicknesses
studied, skin perturbation induced by LFS/SLS is generated in a consistent and similar
manner. In other words, the FTS and STS models are identical in terms of their response to
the LFS/SLS treatment. This important conclusion is consistent with the recent findings by
Seto et al.19
Comparison of log C Values for LFS/SLS-Treated and LFS-Treated Samples—
For LFS-treated FTS, the extent of skin perturbation, as quantified by the log C values, is
statistically similar to both LFS/SLS-treated FTS and LFS/SLS-treated STS. However, as
Table II shows, the log C value corresponding to LFS-treated STS is significantly lower than
those corresponding to the other three skin sample groups tested (pair-wise t-tests comparing
LFS-treated STS to the other three sample groups yields P≤0.006). This interesting finding
follows because: i) in the absence of SLS, skin samples must be treated for much longer
time periods to reach similar skin electrical resistivity values (see Table III), and ii) the
thinner STS model does not respond to the physical enhancement mechanism (cavitation)
associated with LFS in the same manner as the thicker FTS model. Simply stated, the
stresses put on the thinner, less mechanically robust STS during the long LFS treatment
induces significantly greater skin perturbation than that observed in: (i) the more
mechanically robust FTS model, and (ii) the combined chemical/physical enhancement
induced by the shorter LFS/SLS treatment. This finding also shows that, although the skin
electrical resistivity is a good quantitative measure of skin perturbation, the extent to which
it scales with skin permeability depends on both the skin model and skin treatment regimen
used.
Comparison of ε/τ Values for LFS/SLS-Treated and LFS-Treated Samples—
Table II shows that the ε/τ values for the LFS-treated samples decrease with decreasing skin
thickness, and are generally lower than those corresponding to the LFS/SLS-treated samples.
Although the observed differences are not statistically significant to 95% confidence, they
are nevertheless interesting because they provide some insight into the role that SLS plays in
perturbing the skin, when combined with LFS. More specifically, although the LFS/SLS-
treated samples are subjected to 5- to 12-fold shorter treatments (see Table III), these
samples still have higher ε/τ values, suggesting that they are either more porous (larger ε
value) and/or less tortuous (smaller τ value) than those treated only with LFS. It is not likely
that an increase in ε can explain the difference in ε/τ values for LFS/SLS-treated and LFS-
treated skin samples. This is because previous studies have shown that the radius of
impinging cavitation microjets and the overall number of cavitation events observed near the
skin surface decreases in LFS/SLS-treated samples, with respect to samples treated solely
with LFS.11,12 Since cavitation bubble collapse near the skin surface is the primary
mechanism of new pore formation and permeability enhancement for skin treated with LFS/
SLS and LFS, this would in fact suggest that the porosity of LFS-treated samples should be
greater than the porosity of LFS/SLS-treated samples (which is further enhanced because
LFS treatments are an order-of-magnitude longer than LFS/SLS treatments). Therefore, the
most likely explanation for the observed increase in ε/τ in LFS/SLS-treated samples, with
respect to LFS-treated samples, is the ability of SLS to fluidize/disorder lipid bilayers and
expand lacunar regions, thereby creating less tortuous and more direct permeation pathways
through the skin membrane. Note that this explanation is consistent with the findings of
Paliwal et al., who showed that, in LFS-treated skin, the number density of lacunar regions
increases significantly with respect to those in untreated and LFS/SLS-treated skin (which
suggests greater porosity).18 In addition, Paliwal et al. showed that in LFS/SLS-treated skin,
the number density of lacunar regions did not increase with respect to that in untreated skin,
although the total area of the lacunar regions did increase. This suggests increased length
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and connectivity of the lacunar regions, which could be explained by an interconnected
three-dimensional network of pores (which suggests decreased tortuosity).18 Accordingly,
the ability of LFS and SLS to work in concert, in order to permeabilize skin in both a
physical and chemical manner, leads to the observed higher ε/τ values for the LFS/SLS-
treated samples, compared to the samples treated only with LFS.
Reproducibility and Predictability of Skin Perturbation in Samples Treated with LFS/SLS
and LFS
Reproducibility and predictability of skin perturbation are important characteristics of any
skin treatment regimen. Clinically, not all patients have skin with similar thickness,
elasticity, or other biomechanical properties.31,32 Therefore, a robust skin treatment
protocol is ideal. Consequently, examining the data presented in this paper, it is not
surprising that a combination of LFS/SLS is presently used in clinical applications of LFS
(the company commercializing this technology is Echo Therapeutics, Franklin, MA).21,22
An examination of the log P-log R plots shown in Figure 1 reveals much greater variability
in the regression lines shown for samples treated solely with LFS (Figures 1(c) and 1(d)),
compared to those treated with LFS/SLS (Figures 1(a) and 1(b)). This is also shown
quantitatively in Tables I and II, where the 95% confidence intervals for both the slope of
the linear regression and the log C values are broader for the LFS-treated samples (0.33–
0.37 and 0.10–0.13, respectively) compared to those for the LFS/SLS-treated samples (0.09–
0.22 and 0.05–0.09, respectively). Similarly, the r2 values for the linear regressions of the
LFS-treated data (0.53–0.57) are smaller than those of the LFS/SLS-treated data (0.73–
0.92), thus demonstrating that skin perturbation, and the resulting skin permeability
enhancement, are less predictable for skin treated solely with LFS.
Another significant difference between the LFS/SLS-treated and LFS-treated samples is in
the observed trends in treatment times (see Table III). Specifically, samples treated with
LFS/SLS take nearly an order-of-magnitude less time to reach similar skin electrical
resistivities than LFS-treated samples do. Note that the observed decrease in treatment time
is consistent with the previous finding that the energy density threshold required to observe
skin permeability enhancement in LFS/SLS-treated skin is an order-of-magnitude smaller
than that for LFS-treated skin (note that energy density scales with treatment time).11 In
addition, LFS/SLS-treated samples behave in a more predictable manner, where: (i)
treatment times decrease with increasing skin electrical resistivity, and (ii) the treatment
times necessary to reach the various skin electrical resistivity levels considered are not
significantly different for the FTS and STS samples. On the other hand, for FTS samples
treated solely with LFS, treatment times show no statistically significant difference to reach
the three skin electrical resistivity levels reported in Table III (an ANOVA analysis yielded
a p-value of 0.172, which was confirmed by pairwise t-tests at 95% confidence), while the
treatment times for LFS-treated STS samples decrease in a non-linear manner with
increasing skin electrical resistivity levels. In addition, a comparison of treatment times for
the LFS-treated FTS and STS samples reveals that, at the 1.5 kΩ·cm2 skin electrical
resistivity level, the treatment times are statistically similar, while they are statistically
significantly different (95% confidence) at both the 4 and 10 kΩ·cm2 levels. This again
points to the lack of predictability and reproducibility of skin samples treated only with LFS,
where some skin samples respond much more favorably to the LFS treatment than others.
With all of the above in mind, it is quite clear that it is extremely advantageous to treat skin
with a combination of LFS/SLS. Not only are the required treatments much shorter using
LFS/SLS, but also the combined chemical and physical enhancement mechanisms involved
in skin perturbation using LFS/SLS induce much more predictable trends in skin
perturbation than those induced by the purely physical mechanism associated with LFS.
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The most significant implications of our findings involve an improved mechanistic
understanding of the combined effect of LFS and SLS on skin perturbation. Specifically, we
have shown that, although not intuitive, the combination of both a chemical and physical
skin penetration enhancer can, in fact, be less perturbing to the skin than a physical skin
penetration enhancer alone. Furthermore, our results show that the addition of SLS to the
LFS coupling medium not only allows the delivery of permeants in an equivalent manner to
LFS alone, but also induces less perturbation to the skin membrane in a much shorter,
reproducible, and predictable manner. Clearly, the reduction in treatment time in the
presence of SLS is a great advantage clinically, because it would require health personnel an
order of magnitude more time to treat patients with LFS alone. Furthermore, the importance
of decreased skin perturbation and shorter application time is very significant with respect to
patient safety and compliance. Future research in this area should be aimed at identifying
surfactants that can provide similar, or greater, levels of skin permeability enhancement
when combined with LFS, than LFS/SLS, while inducing even less skin perturbation and
irritation. To this end, in vivo studies on the irritancy potential of the LFS/surfactant
treatment of skin should be considered.
CONCLUSIONS
We investigated the effect of SLS on skin perturbation, when utilized simultaneously with
LFS, by treating two skin models, pig FTS and pig STS, with two treatment regimens, LFS/
SLS and LFS, to reach a range of skin electrical resistivity levels. The LFS/SLS treatment
was found to provide consistent extents of skin perturbation, as quantified using the log C
and ε/τ values obtained. Skin samples treated solely with LFS yielded less consistent results,
where the log C values of the FTS and STS skin models were statistically significantly
different. Additionally, the ε/τ values for LFS-treated skin samples were generally less than
those for LFS/SLS-treated samples, suggesting that SLS acting on the skin creates more
direct paths through the skin membrane by the disordering/fluidization of lipid bilayers,
denaturation of keratin fibers, and expansion of lacunar regions. An analysis of the
variability in the log P-log R linear regression parameters and log C values revealed greater
variation in samples treated solely with LFS, resulting in lower r2 values and broader
confidence intervals for the regression parameters and log C values, with respect to LFS/
SLS-treated samples. Additionally, the LFS-treated samples required 5-fold to 12-fold
longer treatment times than the LFS/SLS-treated samples to reach similar skin electrical
resistivity levels. Treatment times for the LFS/SLS-treated samples behaved predictably,
decreasing monotonically with increasing skin electrical resistivity level, showing no
significant difference in treatment times between FTS and STS samples at each of the skin
electrical resistivity levels analyzed. On the other hand, LFS-treated samples were perturbed
in a less predictable manner, with large variations and no statistical significance in treatment
times between the skin electrical resistivity levels considered.
In summary, SLS has a generally positive impact on skin structural perturbation when
utilized in combination with LFS, compared to LFS treatment alone, by: (i) requiring equal,
or less, skin perturbation to reach similar skin electrical resistivity values (as reflected in the
log C values), (ii) reaching similar skin electrical resistivity levels in much shorter treatment
times (about an order-of-magnitude decrease in treatment times), and (iii) inducing skin
perturbation in a significantly more reproducible and predictable manner.
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Figure 1.
Log P-log R plots for LFS/SLS-treated and LFS-treated skin samples. The solid line on each
plot corresponds to the linear regression fitted to each data set. The regression parameters
are listed in Table I.
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Table I
Model validation for the skin treatments and skin thicknesses tested.
Linear Regression Parameters
Treatment Thickness n Slopea r2
LFS/SLS FTS 58 −1.08 ± 0.09 0.92
LFS/SLS STS 37 −1.07 ± 0.22 0.73
LFS FTS 30 −0.98 ± 0.33 0.57
LFS STS 30 −1.02 ± 0.37 0.53
None FTS 8 −1.01 ± 1.48 0.32
None STS 11 −1.80 ± 0.87 0.71
a
Range corresponds to a 95% confidence interval.
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Table II
Structural parameter values for FTS and STS samples treated with LFS/SLS and LFS.
Treatment Thickness n log Ca,b ε/τ · 106a
LFS/SLS FTS 58 −2.96 ± 0.05 45.6 ± 12.7
LFS/SLS STS 37 −2.90 ± 0.09 45.6 ± 13.3
LFS FTS 30 −2.96 ± 0.10 42.0 ± 9.06
LFS STS 30 −2.68 ± 0.13 36.1 ± 10.9
None FTS 8 −3.35 ± 0.15 2.07 ± 0.50
None STS 11 −3.34 ± 0.11 2.81 ± 0.40
a
Range corresponds to a 95% confidence interval.
b
log C is equivalent to the y-intercept of a linear regression of log P vs. log R with a slope equal to −1.
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